Premium
Proteomic analysis of human brain identifies α‐enolase as a novel autoantigen in Hashimoto's encephalopathy
Author(s) -
Ochi Hirofumi,
Horiuchi Izumi,
Araki Norie,
Toda Tosifusa,
Araki Tomohiro,
Sato Kaori,
Murai Hiroyuki,
Osoegawa Manabu,
Yamada Takeshi,
Okamura Ken,
Ogino Tomoaki,
Mizumoto Kiyohisa,
Yamashita Hirohumi,
Saya Hideyuki,
Kira Jun-ichi
Publication year - 2002
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(02)03307-0
Subject(s) - autoantibody , enolase , encephalopathy , thyroiditis , medicine , immunology , antibody , autoimmune disease , pathology , disease , immunohistochemistry
Hashimoto's encephalopathy (HE) is a rare autoimmune disease associated with Hashimoto's thyroiditis (HT). To identify the HE‐related autoantigens, we developed a human brain proteome map using two‐dimensional electrophoresis and applied it to the immuno‐screening of brain proteins that react with autoantibodies in HE patients. After sequential MALDI‐TOF‐MASS analysis, immuno‐positive spots of 48 kDa (p I 7.3–7.8) detected from HE patient sera were identified as a novel autoimmuno‐antigen, α‐enolase, harboring several modifications. Specific high reactivities against human α‐enolase were significant in HE patients with excellent corticosteroid sensitivity, whereas the patients with fair or poor sensitivity to the corticosteroid treatment showed less reactivities than cut‐off level. Although a few HT patients showed faint reactions to α‐enolase, 95% of HT patients, patients with other neurological disorders, and healthy subjects tested were all negative. These results suggest that the detection of anti‐α‐enolase antibody is useful for defining HE‐related pathology, and this proteomic strategy is a powerful method for identifying autoantigens of various central nervous system diseases with unknown autoimmune etiologies.